EU team launches PhI trial of Parkinson's vaccine; GAVI commits up to $300M for Ebola vaccines;

> EU consortium SYMPATH has begun recruiting for a Phase I study of AFFiRiS' Parkinson's vaccine candidate AFFITOPE PD03A. More

> GAVI says it is committing up to $300 million to buy Ebola vaccines and is ready to begin procurement as soon as the World Health Organization (WHO) recommends one for use. Report

> The FDA has awarded Immunovaccine's ovarian cancer vaccine, DPX-Survivac, its fast-track designation. Release

> VaxInnate has kicked off a Phase Ib/II clinical trial of its quadrivalent seasonal influenza vaccine candidate, VAX2012Q, in the elderly. Release

> Vical ($VICL) has completed enrollment in a Phase I/II clinical trial of its therapeutic HSV-2 vaccine. Release

> The National Cancer Institute has awarded MRIGlobal a $3 million contract to produce an HPV vaccine. Report

> The Indonesian Ministry of Health has rolled out Bio Farma's pentavalent vaccine, added to the country's immunization program last year, across all 33 provinces. More

And Finally... The latest entrant into Islamic finance is leading the industry in the new direction of socially responsible investment. More

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.